http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2748005-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a4eb2447942f052018c9705c785bcb2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166 |
| filingDate | 2015-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dd70b1b2fd19a03f346e4e65533accd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c24c97d2c90f0a1a2196070254fa9542 |
| publicationDate | 2020-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2748005-T3 |
| titleOfInvention | Method for predicting response to therapeutic agents for breast cancer and method of treatment for breast cancer |
| abstract | A method of evaluating a treatment for triple negative breast cancer the treatment of which comprises the use of an androgen receptor inhibitor, the method comprising testing a biological sample obtained from a subject to determine whether the biological sample obtained from the subject is classifies as a basal-type subtype or another subtype by: (a) detecting the expression of the set of intrinsic genes listed in Table 1; (b) determining the baseline centroid classifier score of the sample from the expression of the set of intrinsic genes listed in Table 1; (c) determining the luminal centroid classifier A score of the sample from the expression of the set of intrinsic genes listed in Table 1; and (d) calculating the basal and luminal A weighted classifier score from the basal centroid classifier score and the luminal centroid classifier A score according to the following equation: basal and luminal A weighted classifier score = -0, 25 x baseline centroid classifier score + 0.27 x luminal centroid classifier score A where if the baseline and luminal A-weighted classifier score is greater than -0.3, breast cancer treatment comprising an inhibitor of androgen receptor is more likely to be effective in the subject than if the baseline and luminal A-weighted classifier score is less than or equal to -0.3; and wherein the biological sample is selected from the group consisting of a cell, tissue and body fluid and wherein the biological sample comprises breast tissue or cells. |
| priorityDate | 2014-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 196.